about
Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell linesSubtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysisJOINT AND INDIVIDUAL VARIATION EXPLAINED (JIVE) FOR INTEGRATED ANALYSIS OF MULTIPLE DATA TYPES.Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data setGene expression patterns associated with p53 status in breast cancer.Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer.BreakTrans: uncovering the genomic architecture of gene fusionsComparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling.DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome AtlasIntegrated RNA and DNA sequencing improves mutation detection in low purity tumors.Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusMultiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originAn Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer.Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 statusProteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple MetastasesResponse and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancerVirtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer.Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.The molecular basis of breast cancer pathological phenotypes.Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis.Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.The Integrated Genomic Landscape of Thymic Epithelial Tumors.TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases.National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded TissueRNA expression analysis of formalin-fixed paraffin-embedded tumorsIntegrative Molecular Characterization of Malignant Pleural MesotheliomaThe chromatin accessibility landscape of primary human cancersTumor mutational burden is a determinant of immune-mediated survival in breast cancerCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
P50
Q24816504-66FF6526-02D2-4747-8A69-6A3DCC904438Q28391050-6FA32EA5-9B29-428B-9FC1-B55C4590992DQ30642591-2D03E92D-7E89-4614-BDA9-30EA37AD143EQ31142731-359C058A-D2F4-40D1-A014-3E6646E47019Q33265626-6AA61FA8-7DB9-47FA-9688-AA81A5E50A62Q33719480-DB9D6BC6-F3A6-4941-8992-37C3364C90A4Q33744985-D9C70E01-2427-45D5-ADC1-0A4D7D27593EQ33805247-13F9D972-F460-40DD-B8CE-7C87FA464564Q33915083-93F9B5BB-E821-4229-B817-4AB983A1C4DCQ33983489-9B5B077B-8C54-475D-A552-18E8CC63BE93Q34038170-3B449E17-F2A8-4B57-9144-9CAC11A5A5E0Q34123261-EC397C7B-3A98-44C6-A586-CB4E0C882917Q34503941-B7F5C447-6F3F-487F-9831-F735B5EB291AQ34602664-3FD5D8C6-6F3E-4283-9993-102972DEEB4DQ34882515-A25408E3-821E-49B8-8749-0061D45BC15FQ35887828-E8C45742-F933-44B5-A0C8-6131807C45B4Q36214193-FA4ADD99-64C4-4285-8EF5-D15EDC74B44DQ36383626-0B632950-6D0E-4300-8510-4ECBDC5E1582Q36935015-3B54FB98-A82F-4CFE-9AD7-37C4757CC939Q37016288-819FB546-148C-4AE8-AD5A-43C186744C88Q37166436-83B68EF1-0332-42E2-B7F3-5548988306A1Q37348196-402FD6EB-CDF2-48C5-8B4D-7EE5A504C4C0Q37360211-E1D0282A-0D96-4A00-9F71-78F5D3B94617Q37612632-43A87E98-C2B0-4577-AF49-DC1AABBDB35BQ38810349-86209F5D-C4CF-462B-847E-7806D56F2425Q38891922-69C5852C-1E3D-4896-9C2E-82AA2D38D272Q38973005-2AF07403-8DF1-47B8-8597-A2F3E10C04EFQ39175548-C90649D2-1345-422E-A918-3FF2D4F793C3Q39179314-49362CEE-C1A9-4A7E-BCF5-8D0C64A025CCQ45982151-749068EA-CCDF-4180-A73C-38D9891CF8A7Q48148198-B3EE8D31-B37C-417F-AF17-8E81E3D5956FQ48328328-EB5E27FD-0FA5-43A7-BC8F-F9F1A8EF0ED0Q50040409-96A2A4B3-C4EE-4822-B6DA-45E0ECD81A8FQ55287276-2E476D5C-6575-46CC-8E1D-AD18525EDA5CQ57261169-57A3A23C-D4EB-487A-8208-7C5BF40CF749Q57277018-75723D7A-43C2-43D3-B8C6-E6739076CD38Q57461703-C9152102-7642-45F8-B420-B9E04AB57815Q58550709-9987FA5D-AE4E-46CC-B169-ED1A5A3255B6Q58567735-A950B819-0329-45C3-B4C4-C3EFC856936DQ59565062-FAF65508-4C06-4EAB-B50C-0638F5C538F4
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Katherine A Hoadley
@en
Katherine A Hoadley
@nl
type
label
Katherine A Hoadley
@en
Katherine A Hoadley
@nl
prefLabel
Katherine A Hoadley
@en
Katherine A Hoadley
@nl
P31
P496
0000-0002-1216-477X